Advanced search
Publication Cover
Expert Opinion on Biological Therapy Volume 1, 2001 - Issue 6
Submit an article Journal homepage
53
Views
12
CrossRef citations to date
0
Altmetric
Miscellaneous

RASONs: a novel antisense oligonucleotide therapeutic approach for asthma

Lei Tang Epigenesis Pharmaceuticals, Inc., 7 Clarke Drive, Cranbury, New Jersey 08512, USA, Tel.: +1 609 409 3040; Fax: +1 609 409 6126;, E-mail: [email protected]
,
Anthony Sandrasagra Epigenesis Pharmaceuticals, Inc., 7 Clarke Drive, Cranbury, New Jersey 08512, USA, Tel.: +1 609 409 3040; Fax: +1 609 409 6126;, E-mail: [email protected]
,
Kelly Teng Epigenesis Pharmaceuticals, Inc., 7 Clarke Drive, Cranbury, New Jersey 08512, USA, Tel.: +1 609 409 3040; Fax: +1 609 409 6126;, E-mail: [email protected]
,
Jonathan W Nyce Epigenesis Pharmaceuticals, Inc., 7 Clarke Drive, Cranbury, New Jersey 08512, USA, Tel.: +1 609 409 3040; Fax: +1 609 409 6126;, E-mail: [email protected]
,
Yukui Li Epigenesis Pharmaceuticals, Inc., 7 Clarke Drive, Cranbury, New Jersey 08512, USA, Tel.: +1 609 409 3040; Fax: +1 609 409 6126;, E-mail: [email protected]
,
James C Mannion Epigenesis Pharmaceuticals, Inc., 7 Clarke Drive, Cranbury, New Jersey 08512, USA, Tel.: +1 609 409 3040; Fax: +1 609 409 6126;, E-mail: [email protected]
&
Sherry A Leonard Epigenesis Pharmaceuticals, Inc., 7 Clarke Drive, Cranbury, New Jersey 08512, USA, Tel.: +1 609 409 3040; Fax: +1 609 409 6126;, E-mail: [email protected]
 show all
Pages 979-983 | Published online: 23 Feb 2005

Bibliography

  • THORPE DS, EDITH CHAN AW, BINNIE A et al.: Efficient discovery of inhibitory ligands for diverse targets from a small combinatorial chemical library of chimeric molecules. Biochem. Biophys. Res. Commun. (1999) 266(1):62–65.
  • AGRAWAL S: Importance of nucleotide sequence and chemical modifications of antisense oligonucleotides. Biochim. Biophys. Acta. (1999) 1489:53–68.
  • ••Detailed review of advanced chemistriesused with antisense oligonucleotides.
  • WANG H, CAI Q, ZENG X, YU D, AGRAWAL S, ZHANG R: Antitumor activity and pharmacokinetics of a mixed-backbone antisense oligonucleotide targeted to the RI alpha subunit of protein kinase A after oral administration. Proc. Natl. Acad. Sri. USA (1999) 96:13989–13994.
  • •Overview of antisense based therapeutic approaches and programs.
  • CROOKE ST: An overview of progress in antisense therapeutics. Ant/sense Nucleic Acid Drug Dev. (1998) 8:115–122.
  • AGRAWAL S, ZHAO Q: Antisense therapeutics. Curr. Opiri. Chem. Biol. (1998) 2:519–528.
  • BRANCH AD: A hitchhiker's guide to antisense and nonantisense biochemical pathways. Hepatology (1996) 24:1517–1529.
  • COULSON JM, POYNER DR, CHANTRY A, IRWIN WJ, AKHTAR S: A nonantisense sequence-selective effect of a phosphorothioate oligodeoxynucleotide directed against the epidermal growth factor receptor in A431 cells. Mol. Pharmacol. (1996) 50:314–325.
  • KRIEG AM, STEINBERG AD: Potential of antisense technology in the treatment of immunological disorders. OM. Immurio. Ther. (1995) 4:169–179.
  • GURA T: Antisense has growing pains. Science (1995) 270(5236):575–577.
  • WAGNER RW, MATTEUCCI MD, LEWIS JG, GUTIERREZ AJ, MOULDS C, FROEHLER BC: Antisense gene inhibition by oligonucleotides containing C-5 propyne pyrimidines. Science (1993) 260(5113):1510–1513.
  • BOADO RJ, TSUKAMOTO H, PARDRIDGE WM: Drug delivery of antisense molecules to the brain for treatment of Alzheimer's disease and cerebral AIDS. Pharm. Li. (1998) 87(11):1308–1315.
  • PHAN TA, GRAY AM, NYCE JW, MCGINTY JF: Autoradiographic evidence that intrastriatal administration of adenosine A(1) receptor antisense oligodeoxynucleotide decreases adenosine A(1) receptors in the rat striatum and cortex. Brain Res. Ma. Brain Res. (1999) 72(2):226–230.
  • DE SMET MD, MEENKEN CJ, VAN DEN HORN GJ: Fomivirsen: a phosphorothioate oligonucleotide for the treatment of CMV retinitis. Ocul. hillamm. (1999) 7:189–198.
  • GALLANT SP: Therapeutic targets in bronchial asthma pathophysiology. PedMtr. Asthma Allergy Immuriol. (1998) 12:241–251.
  • BOUSQUET J, CHANEZ P, LACOSTE JY, WHITE R, VIC P, GODARD P, MICHEL FB: Asthma: a disease remodeling the airways. Allergy (1992) 47(1):3–11.
  • DRIVER AG, KUKOLY CA, ALI S, MUSTAFA SJ: Adenosine in bronchoalveolar lavage fluid in asthma. Am. Rev Respir: Dis. (1993) 148(1):91–97.
  • BJORCK T: Isolated bronchi from asthmatics are hyper-responsive to adenosine, which apparently acts by liberation of leukotrienes and histamine. Am. Rev Respit: Dis. (1992) 145:1087–1090.
  • •Evidence for adenosine-mediated
  • •• bronchoconstriction in asthmatics.
  • COWARD WR, SAGARA H, CHURCH MK: Asthma, adenosine, mast cells and theophylline. Clin. Exp. Allergy (1998) 3:42–46.
  • •Sensitivity to adenosine enables discrimination between asthmatics and non-asthmatics.
  • POLOSA R, HOLGATE ST: Adenosine bronchoprovocation: a promising marker of allergic inflammation in asthma? Thorax (1997) 52(10):919–923.
  • ALI S, MUSTAFA SJ, METZGER WJ: Adenosine-induced bronchoconstriction and contraction of airway smooth muscle from allergic rabbits with late-phase airway obstruction: evidence for an inducible adenosine A1 receptor. j Pharinacol Exp. Ther. (1994) 268:1328–1334.
  • •A1 receptor upregulation in an animal model of asthma.
  • NYCE JW: Insight into adenosine receptorfunction using antisense and gene-knockout approaches. Trends Pharmacol. Sci. (1999) 20:79–83.
  • GRIESE M, GOBRAN LI, ROONEY SA: Surfactant lipid uptake and secretion in Type II cells in response to lectins and secretagogues. Am. j Physic] (1991) 261:L140–L147.
  • NYCE JW, METZGER WJ: DNA Antisense therapy for asthma in an animal model. Nature (1997) 385:721–725.
  • ••First description of a respirable antisenseand its effects in vivo.
  • ALT S, LEONARD SA, KUKOLY CA et al: Absorption, distribution, metabolism, and excretion of a respirable antisense oligonucleotide for asthma. Am. I Respir. Grit. Care Med. (2001) 163:989–93.
  • ••Description of ADME properties of a respirable antisense in a rabbit model.
  • GRINDEL JM, MUSICK TJ, JIANG Z, ROSKEY A, AGRAWAL S: Pharmacokinetics and metabolism of an oligodeoxynucleotide phosphorothioate (GEM91) in cynomolgus monkeys following intravenous infusion. Antisense Nucleic Add Drug Dev. (1998) 8(1):43–52.
  • ••Pharmacoltinetic properties of an antisensetherapeutic delivered parenterally.
  • ZHANG R, DIASIO RB, LU Z et al: Pharmacokinetics and tissue distribution in rats of an oligodeoxynucleotide phosphorothioate (GEM 91) developed as a therapeutic agent for human immunodeficiency virus type-1. Biochem. Pharmacol (1995) 49(7):929–939.
  • COSSUM PA, SASMOR H, DELLINGER D et al: Disposition of the 14C-labeled Phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats. Pharmacol. Exp. Ther. (1993) 267(3):1181–1190.

Websites

  • wwwisip.cornipipeline.htm ISIS Pharmaceuticals (2001).
  • www.epigenesispharmaceuticals.comi productpipeline.htm EpiGenesis Pharmaceuticals (2001).
  • www.genta.corniprograms.htm Genta Incorporated (2001).
  • www.hybridon.com Hybridon (2001).
  • www.coleypharma.corniclinindex.html Coley Pharmaceutical Group (2001).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.